Overview and Scope
Black lung disease is a chronic and potentially fatal lung disease that affects coal miners and other individuals who work in coal mines or are exposed to coal dust. The disease is characterized by the accumulation of coal dust particles in the lungs, which can lead to inflammation, scarring and damage to lung tissues.
Sizing and Forecast
The black lung disease market size has grown rapidly in recent years. It will grow from $8.44 billion in 2023 to $9.66 billion in 2024 at a compound annual growth rate (CAGR) of 14.5%. The growth in the historic period can be attributed to coal mining industry growth, awareness and education, compensation and benefits, legislative and legal developments.
The black lung disease market size is expected to see rapid growth in the next few years. It will grow to $16.7 billion in 2028 at a compound annual growth rate (CAGR) of 14.7%. The growth in the forecast period can be attributed to public health initiatives, medical advancements, increasing treatment options, advocacy and support organizations. Major trends in the forecast period include advanced diagnostic techniques, research and prevention, healthcare access, technological advancements.
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/black-lung-disease-global-market-report
Segmentation & Regional Insights
The black lung disease market covered in this report is segmented –
1) By Type: Simple Coal Worker’s Pneumoconiosis; Complicated Coal Worker’s Pneumoconiosis; Other Types
2) By Treatment: Oxygen Therapy; Bronchodilators; Lung Transplant; Stem Cell Therapy; Other Treatment
3) By Diagnosis: Biopsy; Imaging; Full Blood Count; Pulmonary Or Lung Function Tests; Physical Examination; Other Diagnosis
4) By End Users: Hospitals And Clinics; Research Organizations And Academic Institutes; Diagnostic Centers And Labs; Other End Users
Top Major Players:
Pfizer Inc.
Johnson and Johnson
Siemens AG
General Electric
F. Hoffmann-La Roche AG
North America was the largest region in the black lung disease market in 2023.
North America was the largest region in the black lung disease market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in black lung disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12988&type=smp
Major Driver Impacting Market Growth
The increasing mining activities are expected to propel the growth of the black lung disease market going forward. Mining activities involve extracting valuable minerals, ores and other geological materials from the earth's crust. Black lung disease is caused by mining activities and inhaling coal mine dust, which contains dangerous carbon-containing particles and affects coal miners. For instance, in January 2022, according to the United States Geological Survey, a US-based water, earth and biological science and civilian mapping agency, global silver mine production climbed marginally in 2021, rising from 23,500 tons in 2020 to an expected 24,000 tons. Therefore, increasing mining activities are driving the growth of the black lung disease market.
Key Industry Players
Major players in the black lung disease market are Pfizer Inc., Johnson and Johnson, Siemens AG, General Electric, F. Hoffmann-La Roche AG, Merck and Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca PLC, Melinta Therapeutics LLC, GlaxoSmithKline PLC, Medtronic PLC, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Toshiba Corporation, Koninklijke Philps N.V., Mayo Clinic, Baxter International Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Perrigo Lab India Pvt. Ltd., Aurobindo Pharma Limited, Hikma Pharmaceuticals PLC, Lupin Limited.
The black lung disease market report table of contents includes:
1. Executive Summary
2. Black Lung Disease Market Characteristics
3. Black Lung Disease Market Trends And Strategies
4. Black Lung Disease Market - Macro Economic Scenario
5. Global Black Lung Disease Market Size and Growth
….
32. Global Black Lung Disease Market Competitive Benchmarking
33. Global Black Lung Disease Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Black Lung Disease Market
35.Black Lung Disease Market Future Outlook and Potential Analysis
36. Appendix
Explore the trending research reports from TBRC:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Interstitial Lung Disease Market report published by Value Market Research, which studies the future outlook of the market.
It includes the size, share, growth, trends, key players, segments and regional analysis in detail during the study year 2020-2027.The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.
The major players in the interstitial lung disease market include Boehringer Ingelheim, Bellerophon Therapeutics, Inc, Bayer, Fujirebio (Miraca), Philips, Merck, Siemens Healthineers.
This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.Get more information on "Global Interstitial Lung Disease Market Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/interstitial-lung-disease-market/download-sampleMarket DynamicsRising incidence and prevalence rates of ILD, a diverse range of pulmonary fibrotic disorders affecting the lungs' alveoli will be the primary driving force behind this market's growth.
The development of standardized and detailed diagnostic systems due to an increase in ILD patients' mortality rate will benefit market growth.
Significant progress made in the research, clinical evaluation, management of several forms of ILD, and introduction of new therapeutic options to treat ILDs will boost the market growth.
Interstitial Lung Disease Market report added by Value Market Research, offering growth, trends, and forecast for each segment along with regional and country analysis.
Further, this report also highlights the regional and country-level market analysis.The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.
The major players in the interstitial lung disease market include Boehringer Ingelheim, Bellerophon Therapeutics, Inc, Bayer, Fujirebio (Miraca), Philips, Merck, Siemens Healthineers.
This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.Get more information on "Global Interstitial Lung Disease Market Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/interstitial-lung-disease-market/download-sampleMarket DynamicsRising incidence and prevalence rates of ILD, a diverse range of pulmonary fibrotic disorders affecting the lungs' alveoli will be the primary driving force behind this market's growth.
The various hindrances to this market's growth are limited treatment options available, low-efficiency rate, and failure to provide a complete cure.
The research report covers Porter’s Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis.
